Phenotype and Proportions within overall WATCH cohort
Phenotype and Proportions within overall WATCH cohort
Male, early-onset (14.0%) Male, early-onset (14.0%)
Female, early-onset (34.7%)
Male, adult-onset (20.8%)
Female, adult-onset (30.5%)
Proportions within biologic (Omalizumab or Mepolizumab, N= 167) cohort
(%, n/N) Proportions within biologic (Omalizumab or Mepolizumab, N= 167) cohort
(%, n/N) 17.4% (29/167) 17.4% (29/167) 34.7% (58/167) 23.4% (39/167) 24.6% (41/167)
Distribution within respective biologic group
(%, n/N), (A) Omalizumab, N=105 15.2% (16/105) 15.2% (16/105) 44.8% (47/105) 18.1% (19/105) 21.9% (23/105)
Mepolizumab, N=62 21.0% (13/62) 21.0% (13/62) 17.7% (11/62) 32.3% (20/62) 29.0% (18/62)
Biologic response within each phenotype (%, n/N) † Omalizumab responder (B) 100% (16/16) 100% (16/16) 80.9% (38/47) 94.4% (17/18) 91.3% (21/23)
Mepolizumab responder (C) 69.2% (9/13) 69.2% (9/13) 70% (7/10) 80% (16/20) 73.3% (11/15)
P-values P-values A 0.004 0.004 0.004 0.004
B 0.135 0.135 0.135 0.135
C 0.893 0.893 0.893 0.893